S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
52-week Low Names To Tip The Upside Scale In Your Favor
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
3 Reasons This Sleeping Giant Is About To Wake Up
KB Home Price Weakness is a Signal to Buy this Cash Machine
New AI Stock Payouts (Ad)
Things to know about California's new proposed rules for insurance companies
Analysts Went All In On These Computer Stocks, Save Your Spot
New AI Stock Payouts (Ad)
How major US stock indexes fared Friday, 9/22/2023
MarketBeat Week in Review – 9/18 - 9/22
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
52-week Low Names To Tip The Upside Scale In Your Favor
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
3 Reasons This Sleeping Giant Is About To Wake Up
KB Home Price Weakness is a Signal to Buy this Cash Machine
New AI Stock Payouts (Ad)
Things to know about California's new proposed rules for insurance companies
Analysts Went All In On These Computer Stocks, Save Your Spot
New AI Stock Payouts (Ad)
How major US stock indexes fared Friday, 9/22/2023
MarketBeat Week in Review – 9/18 - 9/22
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
52-week Low Names To Tip The Upside Scale In Your Favor
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
3 Reasons This Sleeping Giant Is About To Wake Up
KB Home Price Weakness is a Signal to Buy this Cash Machine
New AI Stock Payouts (Ad)
Things to know about California's new proposed rules for insurance companies
Analysts Went All In On These Computer Stocks, Save Your Spot
New AI Stock Payouts (Ad)
How major US stock indexes fared Friday, 9/22/2023
MarketBeat Week in Review – 9/18 - 9/22
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
52-week Low Names To Tip The Upside Scale In Your Favor
WARNING: Mandatory U.S. Dollar Recall is Weeks Away (Ad)
3 Reasons This Sleeping Giant Is About To Wake Up
KB Home Price Weakness is a Signal to Buy this Cash Machine
New AI Stock Payouts (Ad)
Things to know about California's new proposed rules for insurance companies
Analysts Went All In On These Computer Stocks, Save Your Spot
New AI Stock Payouts (Ad)
How major US stock indexes fared Friday, 9/22/2023
MarketBeat Week in Review – 9/18 - 9/22
NASDAQ:TCRX

TScan Therapeutics (TCRX) Stock Forecast, Price & News

$2.65
0.00 (0.00%)
(As of 09/22/2023 ET)
Compare
Today's Range
$2.52
$2.70
50-Day Range
$2.04
$2.94
52-Week Range
$1.45
$6.03
Volume
20,867 shs
Average Volume
189,985 shs
Market Capitalization
$126.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.50

TScan Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
334.0% Upside
$11.50 Price Target
Short Interest
Healthy
0.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.80) to ($1.77) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

447th out of 967 stocks

Biological Products, Except Diagnostic Industry

64th out of 159 stocks


TCRX stock logo

About TScan Therapeutics (NASDAQ:TCRX) Stock

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 that is in Phase I of clinical trial for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-204 that is in Phase I for the treatment of solid tumors. The company also developing TSC-200, TSC-201, TSC-202, TSC-203, and TSC-205 for the treatment of solid tumors. In addition, it engages in the developing vaccines for infectious diseases, such as SARS-CoV-2. The company has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer; and a collaboration agreement with Amgen to identify novel targets in Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

TCRX Price History

TCRX Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Barclays Remains a Buy on TScan Therapeutics (TCRX)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
TScan Therapeutics CFO Brian Silver To Step Down
See More Headlines
Receive TCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TScan Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TCRX Company Calendar

Last Earnings
8/10/2023
Today
9/23/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TCRX
Fax
N/A
Employees
135
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.50
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+334.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-66,220,000.00
Net Margins
-497.11%
Pretax Margin
-497.11%

Debt

Sales & Book Value

Annual Sales
$13.53 million
Book Value
$4.10 per share

Miscellaneous

Free Float
43,864,000
Market Cap
$126.72 million
Optionable
Not Optionable
Beta
0.34
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Gavin MacBeath Ph.D. (Age 53)
    CEO, Director & Interim Principal Financial Officer
    Comp: $650.17k
  • Dr. Stephen J. Elledge Ph.D.
    Co-Founder & Chairman of Scientific Advisory Board
  • Mr. Tomasz Kula Ph.D.
    Co-Founder & Member of Advisory Board
  • Mr. Leiden Dworak
    Principal Accounting Officer
  • Mr. Ray Lockard
    Sr. VP of Technical Operations & Quality
  • Ms. Heather Savelle
    VP of Investor Relations
  • Dr. Zoran Zdraveski J.D. (Age 53)
    Ph.D., Chief Legal Officer & Company Sec.
  • Ms. Ann Hargraves
    Sr. VP of HR
  • Dr. Shrikanta Chattopadhyay M.D.
    Sr. VP of Medical & Translational Medicine
  • Dr. Debora Barton M.D. (Age 47)
    Chief Medical Officer













TCRX Stock - Frequently Asked Questions

Should I buy or sell TScan Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TScan Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TCRX shares.
View TCRX analyst ratings
or view top-rated stocks.

What is TScan Therapeutics' stock price forecast for 2023?

2 equities research analysts have issued twelve-month target prices for TScan Therapeutics' stock. Their TCRX share price forecasts range from $8.00 to $15.00. On average, they expect the company's stock price to reach $11.50 in the next twelve months. This suggests a possible upside of 334.0% from the stock's current price.
View analysts price targets for TCRX
or view top-rated stocks among Wall Street analysts.

How have TCRX shares performed in 2023?

TScan Therapeutics' stock was trading at $1.55 at the beginning of 2023. Since then, TCRX stock has increased by 71.0% and is now trading at $2.65.
View the best growth stocks for 2023 here
.

When is TScan Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our TCRX earnings forecast
.

How were TScan Therapeutics' earnings last quarter?

TScan Therapeutics, Inc. (NASDAQ:TCRX) released its quarterly earnings results on Thursday, August, 10th. The company reported ($0.51) earnings per share for the quarter, beating analysts' consensus estimates of ($0.76) by $0.25. The business had revenue of $3.15 million for the quarter, compared to analyst estimates of $3.75 million. TScan Therapeutics had a negative net margin of 497.11% and a negative trailing twelve-month return on equity of 67.32%.

What ETF holds TScan Therapeutics' stock ?

Simplify Propel Opportunities ETF holds 1,046,916 shares of TCRX stock, representing 2.20% of its portfolio.

When did TScan Therapeutics IPO?

(TCRX) raised $100 million in an initial public offering on Friday, July 16th 2021. The company issued 6,250,000 shares at a price of $15.00-$17.00 per share.

What is TScan Therapeutics' stock symbol?

TScan Therapeutics trades on the NASDAQ under the ticker symbol "TCRX."

Who are TScan Therapeutics' major shareholders?

TScan Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BVF Inc. IL (12.34%), BlackRock Inc. (5.21%), Monashee Investment Management LLC (1.65%), Renaissance Technologies LLC (0.61%), Geode Capital Management LLC (0.48%) and Stifel Financial Corp (0.41%). Insiders that own company stock include Brian M Silver, David P Southwell, Gavin Macbeath, Lynx1 Capital Management Lp, Timothy J Barberich and Zoran Zdraveski.
View institutional ownership trends
.

How do I buy shares of TScan Therapeutics?

Shares of TCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TScan Therapeutics' stock price today?

One share of TCRX stock can currently be purchased for approximately $2.65.

How much money does TScan Therapeutics make?

TScan Therapeutics (NASDAQ:TCRX) has a market capitalization of $126.72 million and generates $13.53 million in revenue each year. The company earns $-66,220,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis.

How many employees does TScan Therapeutics have?

The company employs 135 workers across the globe.

How can I contact TScan Therapeutics?

TScan Therapeutics' mailing address is 830 WINTER STREET, WALTHAM MA, 02451. The official website for the company is www.tscan.com. The company can be reached via phone at 857-399-9500 or via email at tscan@argotpartners.com.

This page (NASDAQ:TCRX) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -